Updates are available Correction dated 2023-05-26
Click to view Correction: https://doi.org/10.1038/s41556-023-01172-2
-
Authors
Cui, Haissi http://orcid.org/0000-0003-3358-8958
Diedrich, Jolene K.
Wu, Douglas C.
Lim, Justin J.
Nottingham, Ryan M.
Moresco, James J.
Yates, John R. III http://orcid.org/0000-0001-5267-1672
Blencowe, Benjamin J. http://orcid.org/0000-0002-4461-0340
Lambowitz, Alan M. http://orcid.org/0000-0001-6036-2423
Schimmel, Paul http://orcid.org/0000-0002-0448-022X
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (327097878)
Human Frontier Science Program (LT000207)
U.S. Department of Health & Human Services | National Institutes of Health (P41 GM103533, R35 GM136216)
Gouvernement du Canada | Canadian Institutes of Health Research (Foundation Grant)
National Foundation for Cancer Research (e National Foundation for Cancer Research)
- License Information
-
More Information
Article History
Received: 28 March 2022
Accepted: 27 February 2023
First Online: 14 April 2023
Change Date: 26 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41556-023-01172-2
Competing interests
: Thermostable Group II Intron Reverse Transcriptase (TGIRT) enzymes and methods for their use are the subject of patents and patent applications that have been licensed by the University of Texas to InGex, LLC. A.M.L. and the University of Texas are minority equity holders in InGex, and A.M.L., some members of A.M.L.’s laboratory, and the University of Texas receive royalty payments from the sale of TGIRT enzymes. The remaining authors declare no competing interests.
